Detection of Anti-Platelet Factor 4 Antibodies in Acute and Chronic Thromboembolic Disease—A Pilot Study
Open Access
- 5 November 2026
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (21) , 9899
Abstract
Heterogeneous antibodies directed against platelet factor 4 (PF4-Abs) are associated with heparin-induced thrombocytopenia (HIT) and vaccine-induced immune thrombocytopenia and thrombosis (VITT). Emerging evidence suggests that these antibodies may also occur in other thromboembolic diseases. In this pilot study, we assessed the prevalence of PF4-Abs in patients with acute thromboembolism and in patients with thromboembolic antiphospholipid syndrome (APS), a chronic autoimmune thrombophilia. Forty patients with acute thromboembolism and 43 patients with APS were included. Both heparin-dependent and heparin-independent PF4-Abs were evaluated using multiple assay platforms, including a prototype chemiluminescence assay for heparin-independent PF4-Abs, an anti-PF4/polyanion IgG chemiluminescence assay, a latex agglutination assay detecting anti-PF4/polyanion IgG/IgM/IgA antibodies, an anti-PF4/heparin IgG ELISA, and functional platelet activation tests. Across the different assays, positivity in at least one assay was observed in 27.5% (11/40) of patients with acute thromboembolism and 27.9% (12/43) of patients with APS. In most antibody-positive patients, no recent heparin exposure was documented. Functional platelet activation was predominantly absent, arguing against a classical HIT- or VITT-like mechanism. Overall, these results demonstrate assay-dependent PF4-Ab positivity in a substantial proportion of patients with acute and chronic thromboembolic conditions. Their clinical and pathogenic relevance remains unclear and warrants further investigation.Keywords
This publication has 36 references indexed in Scilit:
- Characterization of monoclonal and patient-derived antiplatelet factor 4 antibodies in platelet factor 4 and platelet factor 4/polyanion chemiluminescence assaysJournal of Thrombosis and Haemostasis, 2026
- The 2023 ACR/EULAR Antiphospholipid Syndrome Classification CriteriaArthritis & Rheumatology, 2023
- Developing an assay to distinguish between HIT and VITT antibodiesHamostaseologie, 2023
- Platelet-activating anti-PF4 disorders: An overviewSeminars in Hematology, 2022
- Anti-platelet factor 4/polyanion antibodies mediate a new mechanism of autoimmunityNature Communications, 2017
- Prevalence and clinical implications of anti-PF4/heparin antibodies in intensive care patients: a prospective observational studyJournal of Thrombosis and Thrombolysis, 2014
- A novel mechanism of thrombosis in antiphospholipid antibody syndromeJournal of Autoimmunity, 2010
- Platelet factor 4/heparin antibody (IgG/M/A) in healthy subjects: a literature analysis of commercial immunoassay resultsJournal of Thrombosis and Thrombolysis, 2008
- Temporal Aspects of Heparin-Induced ThrombocytopeniaNew England Journal of Medicine, 2001
- Antiplatelet Factor 4—Heparin Antibodies in Patients with Antiphospholipid AntibodiesThrombosis Research, 1999